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Researchers and clinicians have discovered several important concepts regarding the
mechanisms responsible for increased risk of arrhythmias, heart failure, and sudden
cardiac death. One major step in defining the molecular basis of normal and abnormal
cardiac electrical behavior has been the identification of single mutations that greatly
increase the risk for arrhythmias and sudden cardiac death by changing channel-gating
characteristics. Indeed, mutations in several genes encoding ion channels, such as SCN5A,
which encodes the major cardiac Na+ channel, have emerged as the basis for a variety of
inherited cardiac arrhythmias such as long QT syndrome, Brugada syndrome, progressive
cardiac conduction disorder, sinus node dysfunction, or sudden infant death syndrome.
In addition, genes encoding ion channel accessory proteins, like anchoring or chaperone
proteins, which modify the expression, the regulation of endocytosis, and the degradation
of ion channel a-subunits have also been reported as susceptibility genes for arrhythmic
syndromes. The regulation of ion channel protein expression also depends on a fine-tuned
balance among different other mechanisms, such as gene transcription, RNA processing,
post-transcriptional control of gene expression by miRNA, protein synthesis, assembly
and post-translational modification and trafficking. The aim of this review is to inventory,
through the description of few representative examples, the role of these different
biogenic mechanisms in arrhythmogenesis, HF and SCD in order to help the researcher to
identify all the processes that could lead to arrhythmias. Identification of novel targets
for drug intervention should result from further understanding of these fundamental
mechanisms.
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INTRODUCTION
Annually, more than 300,000 cases of sudden cardiac death (SCD)
occur in the United States, representing a major public health
concern (George, 2013). SCD mainly results from severe ventric-
ular arrhythmias, ventricular fibrillation being the most common
underlying arrhythmia. These arrhythmias can be the result of
a variety of structural changes of the heart or ion channel dys-
functions sometimes through an altered expression. During the
last decade, researchers and clinicians have discovered impor-
tant concepts by elucidating the mechanisms responsible for
rare monogenic arrhythmic disorders, so called channelopathies
(Martin et al., 2012; George, 2013). Indeed, one major step in
defining the molecular basis of normal and abnormal cardiac
electrical behavior has been the identification of single muta-
tions that greatly increase the risk for arrhythmias, cardiomy-
opathies, and SCD (for review see Basso et al., 2011; McNally
et al., 2013). Significant technological advances in the study of
the genetics of sudden cardiac death have taken place in the
last decade (Brion et al., 2010). The vast majority of the muta-
tions identified so far are located in the coding regions of gene
encoding ion channel subunits or regulatory proteins and signif-
icantly affect the biophysical properties (gating, ion permeation)
or the membrane expression of key ion channels. Mouse mod-
els of related cardiac arrhythmias, which recapitulate for most
of them the clinical phenotypes of the patients, have helped us
to elucidate the pathophysiological relevance of these mecha-
nisms (Derangeon et al., 2013; Remme, 2013a). However, patients
carrying these mutations remain rare. Heart failure (HF), a syn-
drome caused by significant impairments in cardiac function,
is the leading cause of hospitalization in people older than 65
years in developed countries. HF is a classical situation where
the risk of arrhythmias is increased, contributes substantially to
morbidity and is responsible for SCD, which represents a large
proportion of all deaths in these patients (Janse, 2004; Martin
et al., 2011). In HF, and in other cardiac diseases, arrhythmias
have been shown to be secondary to electrical remodeling i.e.,
altered expression of ion channels (Nattel et al., 2010), studied
mainly at the mRNA level, although post-transcriptional pro-
cesses could also be involved (for review see, Zorio et al., 2009;
Kim, 2013).
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Because of the magnitude of the SCD issue, the opportu-
nities for a real public health impact are significant. SCD is a
major health problem and constitutes one of the most impor-
tant unsolved challenges. Recent medical progresses have had a
remarkable impact on SCD in patients at high risk because of
advanced heart disease or because they are affected by mono-
genic arrhythmias (for review, see Martin et al., 2011). However,
the majority of victims do not fall into these high-risk groups.
Particularly, a significant number of previously healthy young
people have died suddenly and unexpectedly, due to genetic heart
disorders, either structural cardiomyopathies or arrhythmogenic
abnormalities (Brion et al., 2010; Cross et al., 2011). The risk of
fatal arrhythmias may be modulated by genetically determined
variants in key pathways and may become manifest in the face
of environmental triggers such as myocardial ischemia, drugs,
or HF (Anvari et al., 2001; Hu et al., 2007a,b; Mittleman and
Mostofsky, 2011; Amin et al., 2013). Abnormalities in plasma
membrane ion channel function are central to arrhythmogenesis.
Recent studies have provided valuable information on how the
ion channel expression level, localization, and biophysical prop-
erties are regulated, but also revealed that our understanding of
the underlying mechanisms is still limited (Harkcom and Abbott,
2010; Ravens andWettwer, 2011; Rook et al., 2012). Currently, the
research should no longer be restricted to study mRNA expres-
sion (in acquired cardiac diseases) or biophysical processes (in
channelopathies). Although many studies have focused on cell
surface expression of mutant channels, it becomes essential to
expand our fields of investigation to all the molecular processes
responsible for the biogenic properties such as RNA process-
ing, translation and trafficking to understand these fundamental
mechanisms. Indeed, incorrect processing causes many diseases.
This review focuses on examples chosen to illustrate processes
that may account for the malfunction of mutant cardiac channel,
allowing to identify novel targets for drug intervention.
GENE TRANSCRIPTION AND RNA PROCESSING
GENE TRANSCRIPTION AND PROMOTER OR OPEN-READING-FRAME
POLYMORPHISMS
In the last decade, researchers would elucidate inherited arrhyth-
mic disorders by a monogenic approach. But this concept was
enable to explain the incomplete penetrance of arrhythmic dis-
orders and the overlap syndromes. These limitations are typically
observed in SCN5A-related channelopathies (Remme and Wilde,
2008). The SCN5A gene encodes a voltage-sensitive sodium chan-
nel mainly expressed in the cardiac muscle: Nav1.5. Numerous
mutations in SCN5A gene have been associated with different
rare arrhythmic syndromes, such as type 3 long QT syndrome
(LQT3), Brugada syndrome (BrS), cardiac conduction disor-
ders, sick sinus syndrome, atrial standstill and overlap syndromes
(Rook et al., 2012). A good example of overlap syndrome is the
disease associated with the SCN5A 1795insD mutation. Patients
carrying this mutation exhibit bradycardia, conduction disease,
LQT3, and Brugada syndromes (Bezzina et al., 1999). Remme
and co-workers generated a knock-in mouse carrying the mouse
equivalent (1798insD) of the human SCN5A-1795insD mutation
and confirmed that a single SCN5A mutation may indeed be
sufficient to cause the overlap syndrome (Remme et al., 2006).
However, other factors may modify and modulate this clinical
phenotype (Remme et al., 2009; Scicluna et al., 2011). These
factors, such as the age, gender, drug therapy, associated dis-
ease, oligogenic factors, or the genetic background of the patient
may explain the diversity of phenotypes observed for the same
mutation. The predictive power of autonomic dysregulation and
markers such as lipid levels, hypertension, diabetes, and smok-
ing is quite low in subclinical heart disease, the population in
which the majority of SCD occur. Thus, it should be considered
that a genetic element such as a single nucleotide polymorphism
(SNP) could minimize or exacerbate the effect of mutations and
must be considered as a functional genetic element. Although the
identification of genetic modifiers of disease severity in genet-
ically inherited arrhythmias is rare (Scicluna et al., 2008), the
understanding of these diseases will be improved by bioinformat-
ics approaches to identify previously unknown functional genetic
elements and to examine their contributions to arrhythmia sus-
ceptibility (Arking et al., 2004; Brion et al., 2010; Arking and
Sotoodehnia, 2012).
The first level of regulation to study in the “gene to function”
relationship remains the level of gene expression that is directly
associated with the activity of its promoter region, which plays a
central role in the regulation of transcription. In 2006, Bezzina
and collaborators identified a set of 6 polymorphisms in near-
complete linkage disequilibrium in SCN5A gene promoter region.
This variant haplotype, found in about 25% of Asian subjects
and absent in whites and blacks, induces a marked reduction of
reporter activity in cardiomyocytes (Bezzina et al., 2006). The
relationship between SCN5A promoter haplotype and conduc-
tion velocity, was analyzed in a cohort of Japanese patients with
Brugada syndrome without SCN5A mutations and of Japanese
control subjects. This study showed that the variant haplotype
was associated with slowed conduction in normal subjects and
exacerbated conduction slowing in those with Brugada syndrome.
This study provides evidence that genetically determined variable
Nav1.5 transcription occurs in the human heart and is associated
with variable conduction velocity, an important contributor to
arrhythmia susceptibility.
In the same way, Park and collaborators have studied the role
of SCN5A promoter variants and DNA methylation by using a
family-based approach in predicting phenotype severity in a large
kindred with a heterozygous loss-of-function SCN5A mutation
(Park et al., 2012). Affected patients exhibited a mixed phenotype
of Brugada Syndrome and atrioventricular conduction disease
and a marked variation in phenotype severity. During systematic
survey of the SCN5A promoter region, they have identified 2 SNP
in complete linkage disequilibrium. These promoter variants were
significantly associated with disease severity (mild vs. severe phe-
notype). On the contrary, the analysis of genome-wide DNA
methylation profiles did not support a role for the methylation
of SCN5A-related genes. This study suggests that the presence of
specific promoter variants increase the risk of a severe phenotype
in heterozygous carriers of an SCN5A loss-of-function mutation.
These promoter implications on arrhythmogenesis were also
confirmed by in vitro studies. For instance, Yang and collaborators
have identified DNA variants in the proximal promoter region
of SCN5A and determined their frequency in 1121 subjects.
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Interestingly, this population consisted of 88 Brugada syndrome
patients with no mutation in SCN5A coding region, and 1033
anonymized subjects from various ethnicities (Yang et al., 2007).
Variant promoter activity was assayed in CHO cells and neonatal
cardiomyocytes by transient transfection of promoter–reporter
constructs. In vitro functional analysis identified four variants
with significantly reduced reporter activity, up to 62.8% in CHO
cells and 55% in cardiomyocytes. The authors concluded that the
SCN5A core promoter includes multiple DNA polymorphisms
with altered in vitro activity, further supporting the concept of
interindividual variability in transcription of this gene.
An association between promoter variants and increased
arrhythmic risk has also been found for other genes, such as
GJA5, which encodes connexin 40. Two closely linked polymor-
phisms in the promoter of Cx40 gene (−44G→A, rs35594137,
and +71A→G, rs11552588) were suggested to decrease Cx40
promoter activity and to be linked to atrial standstill, when
expressed homozygously and cosegregating with an SCN5A loss-
of-function mutation (Groenewegen et al., 2003), or increased
risk of atrial fibrillation (Firouzi et al., 2004). However,Wirka and
collaborators have shown more recently that the Cx40 promoter
rs35594137 SNP was not associated with altered Cx40 mRNA lev-
els in atria (Wirka et al., 2011). This observation underscores the
difficulty of such studies in terms of understanding the molecu-
lar basis of cardiac arrhythmias: identifying a SNP in a promoter
region is not sufficient, in vivo functional validation is necessary.
In addition, the authors have identified another common SNP
(rs10465885), which alters the configuration of one TATA box
of an alternative Cx40 promoter. A promoter-luciferase assay in
cultured murine cardiomyocytes demonstrated reduced activity
of the promoter containing the minor allele of this SNP. It was
strongly associated with Cx40 mRNA expression and displayed
strong and consistent allelic expression imbalance in human atrial
tissue. It was also associated with early-onset atrial fibrillation.
Several studies have shown an association between
angiotensinogen (AGT) promoter polymorphisms and hyper-
tension. For instance, the A-6G and A-20C polymorphisms in
the promoter region of AGT gene are associated, respectively,
to decreased and increased risks of hypertension (Watkins
et al., 2010; Gu et al., 2011). Hypertension is a risk factor for
left ventricular hypertrophy, which is a powerful predictor of
morbidity and mortality from myocardial infarction, stroke,
and congestive heart failure (Rasmussen-Torvik et al., 2005).
In the same way, Chen and collaborators have described that
the promoter polymorphism G-6A is also associated with non-
familial sick sinus syndrome (Chen et al., 2012). This syndrome,
including profound sinus bradycardia, sinus arrest, sino-atrial
exit block, and tachy-bradycardia, is a group of abnormal heart
rhythms presumably caused by a malfunction of the sinus node
(Dobrzynski et al., 2007). By in vitro approaches, Chen and
co-workers have confirmed that nucleotide G at position −6
modulates the binding affinity with nuclear factors and yields
a lower transcriptional activity than nucleotide A. The authors
concluded that this promoter polymorphism might contribute to
non-familial sick sinus syndrome susceptibility.
It should be noted that the vast majority of the mutations
identified so far in the context of arrhythmic diseases are located
in the coding regions of genes encoding cardiac ion channels
or accessory ion channel subunits. These genetic elements can
cause life-threatening arrhythmias and sudden death in heterozy-
gous mutation carriers as it has been extensively described for
the congenital long QT or Brugada syndromes (for recent review
Amin et al., 2013; Remme, 2013b). The application of the same
kind of genotype-phenotype relationship between promoter vari-
ants and cardiac arrhythmias is a major and critical challenge.
Indeed, potential demographic, environmental, and genetic fac-
tors in conjunction with a mutation, may modify the phenotype
for pathology, and thereby determine, at least partially, the large
variability in disease severity.
In this context, some authors have examined the input of
promoter mutations under pathological conditions. A dele-
tion/insertion polymorphism (4G/5G) within the gene encoding
the plasminogen activator inhibitor 1(PAI-1), has been proposed
as a coronary risk factor (Iwai et al., 1998; Margaglione et al.,
1998). Indeed, a study performed in healthy people showed that
the group with a first-degree relative who had suffered from a
coronary ischemic episode had a higher number of homozygotes
for the deleted allele (4G/4G) of the PAI-1 gene (Margaglione
et al., 1998). Moreover, the 4G/4G and 4G/5G haplotypes have
been associated with a faster onset of acute coronary syndromes
after the first angina pain (Iwai et al., 1998). Variability of the
PAI-1 4G/5G genotype contributes to the variability in circulat-
ing PAI-1 levels, with the 4G/4G genotype being associated with
higher PAI-1 plasma levels. In this context, Anvari and collabo-
rators have tested the hypothesis that the 4G/4G genotype could
promote ischemia-associated malignant ventricular arrhythmias
based on the onset of transient coronary ischemic events. They
have determined the PAI-1 4G/5G genotypes, as well as PAI-1
antigen levels in 2 groups of patients with coronary artery dis-
ease (CAD): one without malignant arrhythmias and one with
a history of SCD (Anvari et al., 2001). They revealed a signifi-
cant association between the 4G allele and the risk for malignant
arrhythmias, with greatest risk in subjects possessing the 4G/4G
genotype. They also demonstrated that a genetically determined
prothrombotic/antifibrinolytic state in patients with CAD may
serve as a marker of the severity of the disease, as observed by
higher PAI-1 levels in the group of SCD survivors.
In Brugada syndrome, loss-of-function SCN5A mutations
have been identified as causative in 20% of cases (Calloe et al.,
2013; Remme, 2013b). However, some authors have also exam-
ined the input of SCN5A mutations under ischemic conditions.
In this context, Antzelevitch and collaborators have enrolled 19
patients developing VF during acute myocardial infarction (AMI)
in order to search for possible complications due to SCN5Amuta-
tions under ischemic conditions (Hu et al., 2007a,b; Oliva et al.,
2009). Among the cohort of 19 patients, one missense muta-
tion (G400A) in SCN5A was detected in a conserved region. An
H558R polymorphism was detected on the same allele. Unlike
the other 18 patients, who each developed 1–2VF episodes dur-
ing AMI, the G400A mutation carrier developed 6 episodes of
VT/VF within the first 12 h. This mutation induced a marked
decrease in sodium peak current. So they have described the
first sodium channel mutation to be associated with the devel-
opment of an arrhythmic storm during acute ischemia. These
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findings also suggest that a loss-of-function mutation in SCN5A
may predispose to ischemia-induced arrhythmic storm.
These two examples suggest that a genetic variant could serve
as a marker of arrhythmic risk in the context of common cardiac
diseases.
GENE TRANSCRIPTION AND mRNA STABILITY
During transcription, the RNA-polymerase generates long
strands of RNA that contain untranslated 5′ and 3′ regions, mul-
tiple exons (amino acid encoding RNA sequences) and introns. It
should be noted that the functions of non-coding RNA sequences
are presently incompletely understood. Regulating the expression
of ion channels at the cell surface begins at the level of gene
transcription and mRNA stability. Thus, pathogenic nucleotide
substitutions, deletions, and insertions can affect mRNA synthe-
sis and stability, thereby altering the amount of mRNA available
for subsequent protein generation. The 3′- and 5′-UTRs are
important in controlling mRNA stability, cellular and subcellular
localization, and translation activation or repression (Matoulkova
et al., 2012).
Mutations in the human ether-a-go-go-related gene (hERG)
result in type 2 long QT syndrome (LQT2). More than 30% of
the LQT2mutations result in premature termination codons. The
hERG gene encodes a K+ channel that contributes to the repo-
larization of the cardiac action potential. Gong and collaborators
have described that hERG mRNA transcripts that contain pre-
mature termination codon mutations are rapidly degraded by
nonsense-mediated mRNA decay (NMD) (Gong et al., 2007).
The NMD is an evolutionarily conserved RNA surveillance
mechanism that recognizes and eliminates transcripts containing
Premature Termination Codons (PTC). This process is increas-
ingly recognized as a mechanism for reducing mRNA levels in
a variety of human diseases (Nagy and Maquat, 1998; Maquat,
2004; Chang et al., 2007). Gong and collaborators investigated
2 nonsense mutations, W1001X and R1014X, in the C-terminal
region of the hERG channel. The primary consequence of the
W1001X and R1014X mutations was the degradation of mutant
mRNA by NMD. In parallel, the two mutations produced trun-
cated hERG channel proteins and reduced hERG current ampli-
tude. More interestingly, the R1014X mutation also caused a
dominant-negative effect on the wild-type hERG channel, which
is expected to result in a severe clinical phenotype. Thus, these
LQT2 nonsense mutations cause a decrease in mutant mRNA
levels by NMD rather than a production of truncated pro-
teins suggesting that the degradation of hERG mutant mRNA
by nonsense-mediated mRNA decay is also a significant mecha-
nism in LQT2 patients (Gong et al., 2007). The same mechanism
was also described in the pathogenesis of the hERG P926AfsX14
frameshift mutation, which is associated with a severe phenotype
(Zarraga et al., 2011).
More recently, Stump and collaborators described another
mechanism for the origin of long QT syndrome in which hERG
transcripts containing the Q81X nonsense mutation escaped
NMD by the reinitiation of translation, resulting in the genera-
tion of N-terminally truncated channels. Because the N-terminus
of hERG contains several essential regions that contribute to
the maintenance of slow channel deactivation, these isoforms
exhibited decreased tail current density, accelerated deactivation
kinetics, reduced resurgent outward current and co-assembled
with wild-type hERG to form heteromeric channels with altered
gating properties. The authors present this reinitiation of transla-
tion as a new mechanism of hERG channel dysfunction in LQT2
(Stump et al., 2012), in which mRNA stability modulation may
induce biophysical changes that contribute to the development of
the pathology.
ALTERNATIVE SPLICING
In the post genomic era, it became clear that the number of genes
in eukaryotic genomes does not reflect the biological complexity
of corresponding organisms. The number of functionally distinct
protein isoforms encoded by eukaryotic genes may at least par-
tially explain this lack of correlation. To explain this diversity, it is
essential to consider alternative splicing as a common eukaryotic
process. Normal mRNA splicing can vary for a single gene prod-
uct, thereby generating multiple transcripts with different coding
regions and/or differing translation efficiencies (Kornblihtt et al.,
2013). Many splicing variants associated with Nav1.5 and hERG
channels have been reported (respectively Shang et al., 2007 and
Farrelly et al., 2003). However, the Nav1.5 channel was chosen to
illustrate this topic in view of its multiplicity of splicing processes.
In general, SCN5A mRNA is derived from 28 different exons
(Figure 1). Exons 2–28 contain the protein-coding sequence,
exon 1, and part of exon 2 further encode the 5′-untranslated
region (5′-UTR), whereas exon 28 also contains the 3′-UTR.
Multiple SCN5A mRNA variants have been detected in the mam-
malian heart, most of which are generated by alternative splicing
and apparently evolutionary conserved mechanisms (Schroeter
et al., 2010).Many studies correlated altered action potential mor-
phology and increased arrhythmia vulnerability with changes in
the Nav1.5 expression level and/or sodium current (INa) density.
Such changes have been frequently reported in common cardiac
diseases such as HF (Borlak and Thum, 2003; Valdivia et al., 2005;
Shang et al., 2007).
FIGURE 1 | Diagram depicting alternative splicing for SCN5A gene.
Multiples mRNA variants were described for the 5′ or 3′-untranslated
regions (respectively A and B) (white rectangle, untranslated region; gray
rectangle, translated region; P, promoter element; , stop codon; ,
polyadenylation site).
Frontiers in Physiology | Cardiac Electrophysiology September 2013 | Volume 4 | Article 254 | 4
Jagu et al. Impact of mutation in SCD
Polymorphisms in the 5′-sequence adjacent to the SCN5A
gene have been linked to cardiac arrhythmias. Shang and col-
laborators have identified three alternative 5′-splice variants (1A,
1B, and 1C) of the untranslated exon 1 in the murine SCN5A
mRNA (Shang and Dudley, 2005). Consistent with playing a reg-
ulatory role in Na+ current, the splice variants differ in relative
abundance during development, with a prominent up-regulation
of exon 1C in an adult compared with a fetal heart. These 5′-
UTRs for SCN5A gene show multiple “Transcription Start Sites”
(TSSs). Previously, nine potential TSSs have been identified in
rat muscle (Sheng et al., 1994), then three other TSSs have been
noted in the human SCN5A gene in sequences preceding the
exon 1A (Yang et al., 2004) and finally Shang and collabora-
tors have positioned two other TSSs associated with exon 1C
(Shang and Dudley, 2005). Adding the possibility of more com-
plex regulation, the total identified promoter region contained
consensus-binding sites for several transcription factors that may
be functionally significant. These results suggest the possibility of
complex transcriptional and translational regulation of the car-
diac sodium channel. Moreover, the SCN5A promoter region is
large and complex including repressor elements, tissue-specific
promoter elements, and three untranslated exon 1 variants. For
instance, the presence of an upstream open reading frame in the
human SCN5A transcript containing exon 1D-derived sequences
was recently identified. This sequence almost completely abol-
ished translation of Nav1.5 (Van Stuijvenberg et al., 2010). One
can easily imagine the pathological consequences of such a com-
plexity.
Many other alternative splicing processes were characterized
for this gene (Rook et al., 2012). Among these, there is a splice
form in coding region, which is associated with development,
knowledge that exceeds the investigation field of arrhythmias.
Nav1.5 possesses a central pore-forming α-subunit, com-
prising four repeat domains (D1–D4), each composed of six
membrane-spanning segments (S1–S6). A major type of alter-
native splicing of voltage-gated sodium channel genes involves
inclusion of two alternative exons 6 (5′ genomic and the 3′
genomic) encoding the D1:S3 segment and the D1:S3/S4 extra-
cellular linker. In developmentally regulated D1:S3 splicing of
Nav1.5, there are 31 nucleotide differences between the 5′-exon
(“neonatal”) and the 3′-exon (“adult”) forms, resulting in 7
amino acid differences in D1:S3-S3/S4 linker region. Onkal and
collaborators (2008) have realized an electrophysiological com-
parison of “neonatal” and “adult” isoforms. They have observed
that the “neonatal” isoform exhibited significant functional dif-
ferences with the “adult” form. The neonatal isoform presents
a shift of steady-state activation toward less negative voltages; it
shows a shift of steady-state inactivation toward more negative
voltages; has much slower activation and inactivation kinetics;
it is associated with significantly greater Na+ influx; it shows a
stronger voltage dependence of time to peak and recovers from
inactivation significantly more slowly (Onkal et al., 2008). In
the same time, the authors also tried to determine the critical
involvement of a lysine residue in this “neonatal” form. Indeed,
they have observed that the K211D mutagenesis in “neonatal”
Nav1.5 resulted in a strong shift from the “neonatal” back to the
“adult” electrophysiological phenotype. By this approach, they
concluded that the negative aspartate (“adult”) to positive lysine
(“neonatal”) substitution was primarily responsible for the effects
of D1:S3 splicing on Nav1.5 biophysical characteristics (Onkal
et al., 2008). Compared to the “adult,” for example, the “neona-
tal” channel was associated with a larger inward current (Na+)
during each opening of the channel. In overall conclusion, the
authors have stated that electrophysiological characteristics of
“neonatal” Nav1.5 are highly likely to have a number of signif-
icant pathophysiological as well as physiological consequences.
Following this characterization, pathological implications have
been attributed to this neonatal form. It was effectively observed
that “neonatal” Nav1.5 is a novel marker with significant clinical
potential for management of metastatic breast cancer (Onkal and
Djamgoz, 2009; Chioni et al., 2010).
Splicing processes within the coding region can also generate
truncated forms of Nav1.5. Dudley and collaborators published
an interesting example of abnormal Nav1.5 splicing regulation in
human HF. This pathological splicing contributes to a reduction
in current of a magnitude likely to contribute to the arrhyth-
mic risk in this condition (Shang et al., 2007; Gao et al., 2011).
Theses authors have observed that HF results in an increase
in two SCN5A mRNA variants, designated Exon 28C (39 bp)
and Exon 28D (114 bp). Compared with the full-length Nav1.5
messenger, these variants are shorter and encode prematurely
truncated, non-functional Na+ channel proteins missing the last
part of intramembrane domain IV, from the S3 (for exon 28C)
or S4 (exon 28D) segments to the C terminus. The physiologi-
cal significance of truncations in exon 28 was tested by making
a gene-targeted mouse model with a nonsense mutation in this
exon between the truncations caused by the E28C and E28D vari-
ants. Experiments performed on cardiomyocytes differentiated
from embryonic stem cells carrying this mutation at the heterozy-
gous state showed a significant reduction in cardiac Na+ current
and conduction velocity (Shang et al., 2007).
But what is the mechanism behind this pathological splicing?
During HF, the splicing factors LUC7L3 and RBM25 are up reg-
ulated (Choudhary and Dudley, 2002). These proteins are able to
bind to the canonical sequence in exon 28 near the splicing sites
of SCN5A variants Exon 28C and Exon 28D. This observation
has significant pathological implications because the authors also
observed that two common features present in HF, Angiotensin
II and hypoxia, were able to induce these splicing factors (Gao
et al., 2011). This observation was consistent with clinical data
suggesting that renin-angiotensin system inhibition and revascu-
larization have antiarrhythmic effects (Moro et al., 2010). This
mechanism of splicing does not appear to be tissue restricted but
can explain other clinical implications as previously described for
cancer (Onkal and Djamgoz, 2009; Chioni et al., 2010).
Are these complex alternative splicing processes characteristic
of SCN5A gene or more generally widespread among ion chan-
nels? Houtman and collaborators published mapping for two
genes encoding the inward rectifier current, KCNJ2 (Kir2.1) and
KCNJ12 (Kir2.2) in dog (Houtman et al., 2012). Defective inward
rectifier current may lead, amongst other features, to severe car-
diac arrhythmias in mouse and man such as ventricular arrhyth-
mias and atrial fibrillation (Anumonwo and Lopatin, 2010). By
Race PCR, Houtman and collaborators demonstrated the status
www.frontiersin.org September 2013 | Volume 4 | Article 254 | 5
Jagu et al. Impact of mutation in SCD
of KCNJ2 as a “two exon” gene with a complete Open reading
Frame (ORF) in the second exon and only one transcription ini-
tiation site was mapped. However, they described four differential
transcription termination sites found downstream of two consen-
sus polyadenylation signals. KCNJ12 gene was found to comprise
three exons, with its ORF located in the third exon. Only one
transcription initiation and one termination site were found for
this channel. In addition, the canine KCNJ2 and KCNJ12 gene
structures were conserved amongst other vertebrates. Contrary to
what has been described for SCN5A, no alternative splicing was
observed for KCNJ2 and KCNJ12 genes (Houtman et al., 2012).
Such investigations may be extended to other channels. Thus,
mutations in two mutually exclusive exons of the gene encod-
ing the human cardiac L-type calcium channel (CaV1.2) were
identified in patients with Timothy syndrome (TS) who exhibit
prolonged QT interval and lethal cardiac arrhythmias. Splawski
and collaborators have discovered that TS was associated with
two CaV1.2 mutations, G406R and G402S. They are located in
alternatively spliced exon 8A, encoding transmembrane segment
S6 of domain I (Splawski et al., 2005). The spliced form of
CaV1.2 containing exon 8 is highly expressed in heart and brain,
accounting for approximately 80% of CaV1.2 mRNAs. G406R
and G402S cause reduced channel inactivation, resulting in main-
tained depolarizing L-type calcium currents. These data indicate
that gain-of-function mutations of CaV1.2 exons 8 and 8A cause
TS. In contrast, the loss-of-function mutations of CaV1.2 chan-
nel in patients with Brugada syndrome produce short QT interval
that could result in sudden cardiac death (Liao and Soong, 2010).
Furthermore, recent reports revealed a linkage of CaV1.2 chan-
nel polymorphismwithmultiple central nervous system disorders
including bipolar disorder, depression, and schizophrenia.
Nevertheless, the channels are not the only cases of genetic
variability affecting gene splicing described to date. Thus, Refaat
and collaborators have worked on the prevalence of mutations in
the RNA splicing protein RBM20 in a large cohort of patients with
dilated cardiomyopathy (DCM) (Refaat et al., 2011). The coding
region and splice junctions of RBM20 were screened in subjects
with DCM. Following this research, 2 common polymorphisms
in this splice factor, rs942077 and rs35141404, were genotyped
in all subjects. Although mutations in RBM20 were observed
in approximately 3% of pathological subjects, no differences in
survival, transplantation rate, and frequency of ICD therapy in
mutation carriers were observed. Despite this apparently nega-
tive result, such studies should be generalized and extended to all
the proteins involved directly or indirectly in the mechanism of
splicing.
TRANSLATIONAL CONTROL BY miRNA AND ALTERNATIVE
TRANSLATION
Improving our knowledge on molecular mechanisms of cardiac
arrhythmias will also necessitate gaining knowledge on post-
transcriptional mRNA regulation.
TRANSLATIONAL CONTROL BY miRNA
Noncoding RNA sequences, with incompletely understood func-
tion, appear to be involved in the post-transcriptional regulation
by microRNAs (miRNA). The complexity of this regulation is still
not completely understood and should represent a novel concept
about combination of basic research and clinical application.
MiRNAs are small noncoding RNAs that regulate the expres-
sion of target 1) by a direct degradation of their target mRNA
following a near-perfect hybridization, but this case is rare or 2)
by binding to sequence that include the 3′ untranslated region
(3′-UTR) of newly synthesized mRNA transcripts by a block of
translation (Figure 2). The human genome is estimated to encode
more than 1000 miRNAs, which are either transcribed as stand-
alone transcripts, often encoding several miRNAs, or generated by
the processing of protein coding gene introns. The miRNAs typi-
cally exert their inhibitory effects on several mRNAs, which often
encode proteins that govern the same biologic process or several
components of a molecular pathway.
Although published studies focusing on miRNAs and cardiac
excitability are still sparse, recent articles have highlighted the
role of miRNAs in cardiac rhythm through regulation of key ion
channels, transporters, and cellular proteins in arrhythmogenic
conditions (Kim, 2013). The available data from experimental
studies demonstrate that miRNAs regulate numerous properties
of cardiac excitability including conduction, repolarization, auto-
maticity, Ca2+ handling, spatial heterogeneity, and apoptosis and
fibrosis. To illustrate this post-transcriptional process, we have
chosen to discuss about two suitable examples.
Drawnel and collaborators have described an interesting
mutual antagonism between inositol 1,4,5′-triphosphate receptor
II (IP3RII) calcium channel and miRNA-133a. This antagonism
regulates calcium signals and cardiac hypertrophy (Drawnel et al.,
FIGURE 2 | Diagram depicting post-transcriptional process by miRNA.
After their transcription, the pri-miRNA were matured in pre-miRNA and
exported to cytoplasm. After digestion by dicer and Risc complex
formation, the mRNA target selection can take place depending on the
quality of the match. When the complementary is near perfect, throughout
the length of the mRNA, cleavage of the messenger will take place leading
to its degradation (A). However, if the setting is only partial, usually in the
3′-untranslated region, a translational repression can take place without any
degradation on the messenger (B). Secondarily, it is possible for the cell to
remove the inhibition and to reuse either definitively destroy the
messenger (C) [3′-UTR: 3′-untranslated region; (A)n: polyadenylation tail].
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2012). Indeed, IP3RII expression is increased in hypertrophic
failing human myocardium. The ectopic calcium released from
these receptors induces pro-hypertrophic gene expression and
may promote arrhythmias. Drawnel and collaborators have inves-
tigated themechanisms that produce up regulation of IP3RII dur-
ing hypertrophic cardiomyocyte remodeling. This study clearly
delineates an anti-hypertrophic role for miR133a that is intrin-
sic to the ventricular myocyte by maintaining low basal IP3RII
expression. The authors have observed that decreased expres-
sion of miR-133a allows IP3RII expression to increase, thereby
promoting hypertrophy. This maintains an appropriate level of
myocyte growth until the balance between miR-133a and IP3RII
is perturbed by pathological stimuli that elicit calcium signals.
The authors have also described a deleterious positive feedback
loop. Indeed, an increase in calcium signals sustains repression
of miR-133a, providing a powerful driving force for patholog-
ical remodeling. In a relevant manner, other pro-hypertrophic
positive feedback loops have been identified involving miRNAs
and the signaling pathways that regulate their expression. This is
the case for miR-1–dependent modulation of insulin-like growth
factor-1 signaling (Elia et al., 2009) and miR-199b–mediated
regulation of dual-specificity tyrosine phosphorylation-regulated
kinase 1a (Dyrk1a), the NFAT negative regulatory kinase (da
Costa Martins et al., 2010). When taken together, these studies
indicate that several reciprocal regulatory loops may be active
within the myocardium under pro-hypertrophic conditions. The
potential clinical implications are interesting. Indeed, miR-133a
activity in vivo is sufficient to mediate pathological cardiac
growth. In particular, infusion of miR-133a antagomir (a miRNA
blocker) is sufficient to induce hypertrophic remodeling in adult
mice (Carè et al., 2007). However, things remain to be clarified
as other authors have observed that miR-133a maintains cardiac
function via anti-apoptotic and anti-fibrotic effects within the
adult myocardium (Matkovich et al., 2010). But this observation
does not take away the relevance of this mode of regulation in our
arrhythmia issue.
To illustrate the cardiovascular consequences of this post-
transcriptional regulation, we will focus on Friedreich ataxia
(FRDA), which is an autosomal recessive neurodegenerative dis-
ease arising from mutations in both alleles of the frataxin gene
(FXN). In approximately 97% of cases the mutant alleles have
an expansion of a GAA trinucleotide repeat in intron 1 of FXN
that reduces the amount of frataxin available to assist with mito-
chondrial iron efflux and increases sensitivity to oxidative stress,
resulting in cell damage and death due to excess production of
free radicals (Cossee et al., 1997; Wong et al., 1999). As well as
the neurological features of the disease, a large proportion of
FRDA patients develop cardiac abnormalities of cardiac struc-
ture or function. Indeed, heart failure and cardiac arrhythmias
are thought to be the most important causes of death in FRDA
(De Michele et al., 1996).
Kelly and collaborators have used a tag SNP approach to
investigate the association of genetic variability in three impor-
tant genes of the Renin–Angiotensin–Aldosterone system (RAAS)
with measures of cardiac phenotype severity in FRDA (Kelly
et al., 2011). The genes selected for investigation were AGTR1,
which encodes AT1R, the predominant angiotensin-II receptor
in the cardiovascular system, and the ACE and ACE2 genes,
which encode the converting enzymes directly involved in the
production and degradation of angiotensin-II. On the basis of
this investigation, the authors have identified rs5186, a SNP in
AGTR1, as a potential modifier of the cardiac phenotype in a large
population of FRDA patients. The rs5186 SNP is a functional
A/C polymorphism that occurs in the target sequence of a regula-
tory microRNA, miR-155, in the 3′ untranslated region of AGTR1
(Martin et al., 2007). However, the rs5186 C allele interrupts base-
pair complementarily between miR-155 and the cis-regulatory
target site, decreasing the ability of miR-155 to bind, thereby
increasing the expression of AT1R (Kelly et al., 2011). The unex-
pected and intriguing finding of this study was that the C allele
of rs5186 was more common in this cohort of FRDA patients
than in a healthy control population. Further investigation of
the prevalence and cardiovascular effects of rs5186 in other large
FRDA populations is required, but it appears that this polymor-
phism should present a protective effect, resulting in increased
survival. Indeed, the prohypertrophic cardiac effects assigned
to this polymorphism, confer a survival advantage for FRDA
patients that present this SNP. Future studies have to assess the
activity of miR-155 in FRDA patients, as it is the likely mecha-
nism by which rs5186 modifies the cardiac phenotype, but these
observations underline the importance of this mode of regula-
tion in cardiovascular remodeling. Despite many recent article
withdrawals, the current literature on miRNAs is rich and alter-
ations of this mode of post-transcriptional regulation need to
be systematically studied in our investigations of arrhythmia
mechanisms.
ALTERNATIVE TRANSLATION
Another molecular mechanism potentially allowing a single
mRNA to produce several proteins is alternative translation (for
review, see Kochetov, 2008).
It is widely established that an eukaryotic mRNA typically con-
tains one translation start site and encodes a single functional
protein product. In mammalian translation systems the consen-
sus sequence is “GCCRCCAUGG” in positions near the start AUG
codon (Kozak, 2005). However, it is now well-documented that a
single mRNA may code for multiple proteins based on utilization
of alternative initiation codons. “Non-AUG codons,” as well as the
classical AUG start codon, should be jointly considered in mech-
anisms for translation of mRNAs. These “non-AUG codons” are
represented by the codons CUG, GUG, UUG, AUA, and ACG.
These alternative Translation Initiation Sites (aTIS) give new
opportunities to the cell for their protein synthesis by increasing
the number of functionally novel protein isoforms encoded by
genes, which present non-AUG codons. However, open-reading
frames started from alternative start codons can commonly be
located in different positions. The proteins resulting from these
aTIS can be unrelated. Nevertheless, in most cases, the “non-
AUG codons” respect the main ORF and lead to the synthesis
of either N-end truncated or N-end extended isoforms of the
CDS-encoded protein, commonly rather small. At the sight of this
new knowledge, polymorphisms or mutations located within or
downstream of the canonical ATG codon of candidate sequences
should be studied with renewed interest.
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It is well-established that the N-end segment of proteins fre-
quently contains secretory signals. Thus, these isoforms can differ
in the protein N-end segment and may be delivered to different
compartments and present different subcellular localizations. In
this context, this process takes all its full meaning for channel
trafficking. One should nevertheless be cautious about any rapid
conclusion. Indeed, channels have the added complexity of pos-
sessing several transmembrane spanning domains with numerous
signal sequences, not restricted to the amino terminal, to be tar-
geted to plasma membrane. For example, Lu and collaborators
have described that multiple topogenic determinants cooperate
during Kv1.3 voltage-gated K+ channel translocation. Only the
transmembrane segment S2 likely functions as the initial sig-
nal sequence to determine Kv1.3 N-terminus topology (Tu et al.,
2000). Thus, the changes in the N-terminus portion of a given
channel by aTIS cannot always explain alone the channel traffick-
ing defect. So in this context, aTIS identification must be taken
into account with caution on an individual basis according to the
considered channel.
Numerous mammalian regulatory proteins utilize aTIS as
critical regulators that control distinct biological functions like
metabolism, intracellular signal transduction, transcription and
gene expression, growth mechanisms, and related cellular func-
tions (Kochetov, 2008). And the number of experimentally veri-
fied examples of alternative translation is growing rapidly.
Nevertheless, it should be noted that alternative translation
initiation is a rare process in mammalian mRNA. In this context,
bioinformatics evaluations of 5′-UTR sequences of mammalian
mRNAs will represent a critical opportunity to characterize new
aTIS in mRNA sequences that have been experimentally involved
in pathologies. In the field of ion channels, a computational
analysis of aTIS performed by Wegrzyn and collaborators a
few years ago suggested that the calcium channel γ8 ancillary
subunit (CACNG8) contains at least one alternative initiation
site (Wegrzyn et al., 2008). This protein was recently identi-
fied as a regulator of the main human heart L-type calcium
channel, CaV1.2 (Yang et al., 2011). Other genes involved in car-
diovascular functions, such as the Vascular Endothelial Growth
Factor (VEGF) have also been shown to contain aTIS (Wegrzyn
et al., 2008). The ability to define aTIS through computational
analyses can be of high importance for genomic analyses to
provide full predictions of translated mammalian and human
gene products required for cellular functions in health and dis-
ease. Whether aTIS plays a role in cardiac electrical activity and
more broadly in cardiovascular physiopathology remains an open
question.
POST-TRANSLATIONAL MODIFICATIONS AND TRAFFICKING
A recent bibliography reflects quite well this mode of regula-
tion. Post-translational modification of cardiac ion channels is a
cellular mechanism for maintaining the rhythmicity of the heart-
beat. Therefore, several studies have made it clear that extensive
post-translational modifications may modulate cardiac channel
expression levels, localization, and gating.
The glycosylation is one of the most common post-
translational modifications. The Nav1.5 protein harbors multiple
evolutionary conserved amino acid motifs for N-glycosylation in
its extracellular domain. Although the precise molecular compo-
sition of the N-glycans in cardiomyocytes and their attachment
sites have not been determined yet, their presences in cardiac
Nav1.5 and impact on channel gating have been recognized.
Thus, Zang and collaborators have described that glycosylation
influences voltage-dependent gating of cardiac and skeletal mus-
cle sodium channels (Zhang et al., 1999). The contribution of
sugar residues to channel gating was examined in transfected cells
pretreated with various glycosidase and enzyme inhibitors to deg-
lycosylate channel proteins. Pretreating transfected cells caused
depolarizing shifts of steady-state activation of hH1a (human
isoform of Nav1.5). These data clearly suggested that glycosyla-
tion differentially regulates sodium channel function in heart and
skeletal muscle myocytes. The same observation was done for the
adult rat ventricular myocytes (Stocker and Bennett, 2006). In
this context, Johnson and collaborators have described interesting
observations on the glycosylation of β-1 subunit of voltage-gated
sodium channels (Nav) (Johnson et al., 2004). Nav are composed
of a pore-forming alpha subunit and often one to several mod-
ulating beta subunits. The fully sialylated ß1 subunit induces a
uniform hyperpolarizing shift in steady state and kinetic gating of
the cardiac and two neuronal alpha subunit isoforms. Moreover,
Johnson and collaborators have observed that under conditions of
reduced sialylation, the ß1-induced gating effect was eliminated.
These observations are consistent with the fact that the mutation
of ß1 N-glycosylation sites abolished all effects of ß1 on channel
gating. Thus, as it has been shown that glycosylation could dif-
fer according to the location within the heart tissue (Montpetit
et al., 2009) and as electrical remodeling in cardiac disease is usu-
ally ascribed to altered expression and distribution of ion channel
proteins such as Nav1.5, the location of any mutation in these
consensus sites of modification should be considered as probable
causes of arrhythmia occurrence.
This type of argument can obviously be extended to other
channels. Chandrasekhar has recently described that an essential
regulatory subunit of the cardiac IKs potassium channel complex,
KCNE1, is glycosylated at threonine-7 in vivo (Chandrasekhar
et al., 2011). Mutations that prevent glycosylation at this amino
acid result in IKs channel complexes that are unable to efficiently
traffic to the plasma membrane. Indeed, examination of these
mutants revealed that complexes that lack N-terminal glycans
adjacent to the N-terminus were functionally similar to wild type
(WT), but had significantly reduced cell surface expression. Thus,
mutations on threonine-7 directly suppress the O-glycosylation
site and have a dramatic effect on biogenesis and anterograde
trafficking of the protein complex, yielding unglycosylated and
mono-N-glycosylated complexes that are trafficking defective and
compromised, respectively. These observations provide a cellular
mechanism for a KCNE1 mutation on threonine-7 that may be
associated with cardiac arrhythmias.
The glycosylation is a critical regulation, but other types of
post-translational modifications are not to be neglected, such as
phosphorylation. In this context, Nav1.5 and ß-adrenergic recep-
tors colocalize to caveolin domains that participate in membrane
trafficking. Yarbrough and collaborators have shown that under
stimulation of beta-adrenergic receptors, a mechanism involving
the alpha subunit of the stimulatory heterotrimeric G-protein,
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Galpha(s), promotes the presentation of cardiac sodium channels
associated with caveolar membranes to the sarcolemma, leading
to an increase in sodium current amplitude (Yarbrough et al.,
2002). In addition, Zhou and collaborators have demonstrated
that the activation of cAMP-dependent protein kinase (protein
kinase A) secondary to the stimulation of beta-adrenergic recep-
tors can potentiate INa by two processes: a fast saturable and a
slow unsaturable component. The fast component involves direct
channel phosphorylation events regulating the kinetics and volt-
age dependence of channel gating, while the slow component
of PKA-dependent INa potentiation is due to enhanced traf-
ficking and insertion of additional functional channels into the
membrane. It should be noted that the I-II cytoplasmic inter-
domain linker loop is critical for this effect (Zhou et al., 2000).
However, other critical sites have been characterized. The I-II
interdomain linker of the channel contains 3 sites with the RXR
motif known to mediate retention of proteins in the endoplasmic
reticulum. The PKA-mediated increase in Na+ current was com-
pletely abolished when all 3 sites were eliminated (Zhou et al.,
2002). These results demonstrate that both phosphorylation and
the presence of putative ER retention signals are required for
the PKA-mediated increase in cardiac Na+ current. These obser-
vations may have important physiological consequences for the
increase in cardiac conduction velocity observed with sympa-
thetic stimulation and the genesis of re-entrant arrhythmias in
ischemic myocardium. Herren and collaborators focussed on the
molecular and functional aspects of Na+ channel phosphoryla-
tion, which is potentiated in heart failure and has been causally
linked to cardiac arrhythmias (Herren et al., 2013).
The oxidation/nitrosylation is also one of the critical and ubiq-
uitous post-translational modification systems for the regulation
of cardiac ion channels (for reviews Gonzalez et al., 2009; Herren
et al., 2013). S-nitrosylation consists of the addition of a nitric
oxyde (NO) group to the thiol moiety of a cysteine residue.
Several ion channels are reportedly redox responsive. For exam-
ple, Xu and collaborators have explored the mechanism of NO
action on the cardiac calcium release channel, of the sarcoplas-
mic reticulum, the type 2 ryanodine receptor (Xu et al., 1998).
They have described that the S-nitrosylation led to progressive
channel activation, which was reversed by denitrosylation. In con-
trast, its oxidation had no effect. So this channel can differentiate
nitrosative from oxidative signals. The authors suggest that NO
and related molecules may regulate excitation-contraction cou-
pling through discrete mechanisms. On the one hand, they can
inhibit the L-type channel via cGMP; on the other hand, they sen-
sitize the muscle to Ca2+-induced Ca2+ release. So the cardiac ion
channels subserving excitation-contraction coupling are poten-
tially regulated by S- nitrosylation. In the same way, the sodium
channel is rich in cysteine and the metabolic state is also inti-
mately coupled to sodium current. However, this process appears
to have tissue specificity. Indeed, a full S-nitrosylationmotif of the
acid base type is found in the Nav of sensory neurons, but only
partial in the heart (Li et al., 1998). As for the ryanodine receptor,
it is possible that beside S-nitrosylation, Nav channels could be
regulated also by cysteine oxidation (Evans and Bielefeldt, 2000).
Ueda and collaborators have described an association of this post-
translational regulation with inherited long QT syndrome (Ueda
et al., 2008). They have identified a missense mutation by direct
sequencing of the gene encoding alpha1-syntrophin (SNTA1),
a member of the dystrophin-associated proteins normally serv-
ing as a scaffold protein for the neuronal nitric oxide synthase
(nNOS) and the plasmalemmal calcium pump PMCA, an inter-
action that results in inhibition of NO production. The SNTA1 is
also known to associate with Nav1.5. Syntrophin mutation results
in a disruption of the PMCA-NOS1 complex and favors interac-
tion of NOS1 with the Na+ channel. Release of PMCA increases
NOS1 activity promoting S-nitrosylation of Nav1.5 and thereby
increasing late Na+ currents at the origin of LQTS-susceptibility.
Another interesting mechanism is the potential dominant-
negative effect due to a heterozygous expression of a mutated
form. Type 2 long QT syndrome involves mutations in the human
ether a-go-go–related gene (hERG or KCNH2) (Keller et al.,
2005), which encodes Kv11.1 channel. Kv11.1 channel current,
because of its unique slow activation and deactivation gating
kinetics relative to its rapid kinetics of inactivation and recov-
ery from inactivation, plays a significant role in late repolariza-
tion in the mammalian heart. As T421M, a mutation in the S1
transmembrane spanning domain of Kv11.1, was identified in
a resuscitated patient, Balijepalli and co-authors have assessed
its biophysical, protein trafficking, and pharmacological conse-
quences in adult rat ventricular myocytes (Balijepalli et al., 2012).
The T421M mutation markedly altered the voltage dependence
and kinetics of both Kv11.1 activation and deactivation but had
minimal effects on the rates of inactivation and recovery from
inactivation. Furthermore, interestingly, for coexpressed wild-
type and T421M-Kv11.1 channels, different dominant-negative
interactions govern protein trafficking and ion channel gating,
and these are likely to be reflected in the clinical phenotype.
Malfunction may also result from defects in the multipro-
tein machinery specialized in channel membrane targeting. In
this context, Wu and collaborators have described MOG1, a
small protein that is highly conserved from yeast to human, as
a critical co-factor for Nav1.5. This protein, expressed in both
atrial and ventricular tissues with predominant localization at
the intercalated discs, can modulate the function of Nav1.5 (Wu
et al., 2008). MOG1, which interacts physically with Nav1.5,
increases sodium current density by an increase in the num-
ber and/or availability of Nav1.5 on cell surface. In addition to
increased trafficking of Nav1.5 to the plasma membrane, MOG1
may reduce the turnover of Nav1.5 localized on the plasma
membrane.
Thus, genetic mutations in MOG1 may affect the expres-
sion and function of Nav1.5, leading to Brugada syndrome
or other types of lethal arrhythmias. Indeed, Kattygnarath
and collaborators have reported by genetic screening that the
MOG1 missense mutation E83D could affect Nav1.5 activity and
provide molecular and clinical evidence that this MOG1 loss-of-
function mutation is linked to Brugada syndrome physiopathol-
ogy (Kattygnarath et al., 2011). As expected, this mutant exerted
a dominant-negative effect on wild-type MOG1 and reduced
Nav1.5 channel trafficking to the cell surface. Similarly, Olesen
and collaborators have screened MOG1 for variants in 197 young
patients with lone atrial fibrillation and 23 patients with Brugada
syndrome and identified a novel nonsense variant mediating a
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premature stop codon, p.E61X (Olesen et al., 2011). Their het-
erologous expression data on p.E61X mutant showed MOG1 loss
of function. This mutant completely failed to increase the sodium
channel current compared to wild-type MOG1. Nevertheless,
this variant seemed to have a higher frequency in patients com-
pared to control subjects but the difference was not statistically
significant. Also in this context, Chakrabarti and collaborators
have recently hypothesized that MOG1 can serve as a thera-
peutic target for sodium channelopathies. They have observed
that this co-factor can enhance plasma membranes trafficking
of mutant sodium channels and rescue the reduced sodium
current associated with Nav1.5 mutations leading defects in traf-
ficking (Chakrabarti et al., 2013). These results indicate that
MOG1 could also be a potential Brugada syndrome modifier
gene and could explain part of the variable penetrance of the
pathology. MOG1 is not the only example of modulation of
trafficking for Nav1.5 by a chaperone protein. For example,
Ishikawa and collaborators have found that two missense muta-
tions in the gene encoding the sarcolemmalmembrane-associated
protein (SLMAP), Val269Ile and Glu710Ala, affect Nav1.5 mem-
brane surface expression (Ishikawa et al., 2012). These mutations
in SLMAP, which ultimately reduce Nav1.5 current, may cause
Brugada syndrome via modulating the intracellular trafficking
of Nav1.5.
These defaults of trafficking caused by mutations have been
described for many other cardiac ion channels, including KCNQ1
potassium channel, Sato and collaborators have investigated the
functional alterations caused by 2 KCNQ1 mutations, a deletion
(delV595) and a frameshift (P631fs/19), which were identified
in patients with autosomal-recessive LQTS not accompanied by
hearing loss (Sato et al., 2009). Functional analyses showed that
bothmutations impaired cell surface expression due to trafficking
defects. The mutations severely affected outward potassium cur-
rent. It was found that delV595 impaired the binding and
assembly of KCNQ1 subunits, whereas the P631fs/19 mutant
channel was retained in endoplasmic reticulum due to the newly
added 19-amino acid sequence containing two retention motifs
(R(633)GR and R(646)LR. In the same manner, a channel may
present multiple kinds of abnormalities. Limberg and collabo-
rators have identified two novel heterozygous KCNJ2 mutations
(p.N318S, p.W322C) located in the C-terminus of the Kir2.1
potassium channel subunit in a large set of patients with con-
genital long-QT syndrome (Limberg et al., 2013). While the
N318S mutants regularly reached the plasma membrane, W322C
mutants primarily resided in late endosomes. The co-expression
of N318S orW322Cwith wild-type Kir2.1 reduced current ampli-
tudes by 20–25% due to defective channel trafficking (W322C)
or gating (N318S). Thus, understanding the dynamics of car-
diac channel surface expression and their potential trafficking
abnormality has become even more essential.
CONCLUSIONS
Thus, at the sight of the multiplicity of mechanisms regulating
ion channel protein expression, such as gene transcription, RNA
processing, post-transcriptional control of gene expression by
miRNA, protein synthesis, assembly and post-translational mod-
ification and trafficking, polymorphisms possibly affecting these
mechanisms should be investigated in our work of understand-
ing new processes at the origin of arrhythmogenesis, not only as
phenotype modulators of genetically-inherited arrhythmias, but
also as putative a arrhythmic substrates in more common diseases
such as cardiac hypertrophy and heart failure.
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